Session Description:
This session explores the intricate interactions between novel cancer therapies and kidney function. Participants will gain a deeper understanding of the renal and electrolyte complications arising from new and emerging cancer treatments, including targeted therapies and immunotherapies. By analyzing real-world case studies and evidence-based practices, clinicians will be better equipped to recognize, manage, and mitigate these complications effectively. This session will also offer a comprehensive guide for establishing and operating an onconephrology clinic, as well as best practices for interdisciplinary collaboration.
Learning Objectives:
1. Identify the mechanisms by which novel cancer therapies can lead to renal complications, including AKI and electrolyte abnormalities, and review the common clinical presentations and diagnostic approaches.
2. Distinguish immune-related kidney injury from other etiologies of AKI in cancer patients and formulate an evidence-based approach for managing ICI-associated renal toxicity.
3. Outline the key considerations and steps for setting up an onconephrology clinic. Recognize the importance of interdisciplinary collaboration in managing onconephrology patients.
Time | Session |
---|---|
9:45 a.m.
10:03 a.m.
|
IK01-01
|
10:03 a.m.
10:21 a.m.
|
IK01-02
|
10:21 a.m.
10:39 a.m.
|
IK01-03
|
10:39 a.m.
10:57 a.m.
|
IK01-04
|
10:57 a.m.
11:15 a.m.
|
IK01-05
|